A large retrospective analysis of electronic health record data from community oncology practices across the United States has revealed substantial variation in the uptake and timing of mismatch repair and microsatellite instability testing among patients with metastatic solid tumors. The study documented that testing prevalence diverges sharply by tumor type, with uptake lagging notably in non-colorectal cohorts.
Published in Frontiers in Oncology by researchers from Merck, Ontada, and The US Oncology Network, the study tracked real-world testing patterns and evaluated demographic and clinical factors associated with test receipt. Despite established recommendations supporting testing across various advanced malignancies, the extent to which community practices routinely conduct these assessments prior to administering systemic therapy has presented a critical knowledge gap.
The investigative team examined longitudinal electronic health record data from 30,177 adult patients diagnosed with metastatic colorectal, endometrial, gastroesophageal, or prostate cancer between January 1, 2018, and June 30, 2023. The study cohort comprised 11,407 patients with colorectal cancer, 2,665 with endometrial cancer, 4,246 with gastroesophageal cancer, and 11,859 with prostate cancer. Patients were followed continuously from their initial diagnosis of metastatic disease until their last documented clinical visit or death through December 31, 2023.
Descriptive evaluations showed that overall testing prevalence differed significantly across tumor groups. Testing rates reached 89.2 percent among patients diagnosed with metastatic colorectal cancer, representing the highest uptake observed in the study. In contrast, testing prevalence among patients with metastatic prostate cancer was markedly lower at 37.0 percent. The researchers observed intermediate testing levels within the remaining cancer cohorts, underscoring that testing adoption has not occurred uniformly across clinical indications despite shared metastatic disease classifications.
The study also assessed the clinical timing of biomarker assessment, uncovering that testing was frequently delayed until after critical therapeutic milestones had passed. Across all four analyzed tumor types, receipt of testing prior to the formal diagnosis of metastatic disease was relatively uncommon, ranging from 3.8 percent to 34.8 percent. Furthermore, testing completed prior to the initiation of first-line systemic treatment remained similarly infrequent, spanning between 5.1 percent and 42.8 percent across the individual disease cohorts. These findings indicate that a substantial proportion of patients who underwent testing had already commenced or selected their initial systemic regimens before biomarker results were available.
Multivariable logistic regression modeling evaluated specific factors associated with whether a patient received mismatch repair or microsatellite instability testing. Compared with patients in the colorectal cancer cohort, patients diagnosed with endometrial, gastroesophageal, or prostate cancers demonstrated significantly lower odds of undergoing testing. Patient age was also linked to lower odds of testing, as older individuals were less likely to be evaluated. Additionally, current tobacco use was associated with decreased odds of testing, though the authors emphasized that the interpretation of this tobacco association is limited by substantial missingness within patient smoking histories.
The investigators concluded that despite observed increases in testing uptake over time, testing rates remain suboptimal in several metastatic cancer populations. Because testing was frequently executed after initial treatment decisions were established, opportunities to systematically integrate biomarker findings into frontline precision therapy planning were constrained across real-world community settings.
Subject of Research: Real-world mismatch repair and microsatellite instability testing patterns across metastatic solid tumors
Article Title: Real-world MMR/MSI testing patterns and factors associated with uptake across metastatic solid tumors: insights from a pan-tumor analysis in US community oncology
Article References: Li, S., Brown-Bickerstaff, C., Banuelos, R., Conkling, P., Marupuru, S., & Zhang, Y. (2026). Real-world MMR/MSI testing patterns and factors associated with uptake across metastatic solid tumors: insights from a pan-tumor analysis in US community oncology. Frontiers in Oncology, 16, Article 1844385. https://doi.org/10.3389/fonc.2026.1844385
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1844385
Keywords: mismatch repair, microsatellite instability, MMR testing, MSI testing, metastatic solid tumors, colorectal cancer, endometrial cancer, gastroesophageal cancer, prostate cancer, precision oncology, biomarker testing patterns, real-world data, community oncology, electronic health records, systemic treatment, first-line therapy, cancer epidemiology
News Source: Nathaniel Bowman. (November 11, 2026). MMR and MSI Testing Varies Widely Across Metastatic Solid Tumors. Scienmag.



